Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sirius XM Holdings Inc (SIRI) vs TransMedics Group Inc (TMDX) Price & Performance

Sirius XM Holdings IncTrade
TransMedics Group IncTrade

Price performance (Past 24H)

Key statistics

Sirius XM Holdings Inc vs TransMedics Group Inc — how do they compare? Sirius XM Holdings Inc trades at $26.71 (market cap $8.87B), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: Sirius XM Holdings Inc is far larger — about 3.2× TransMedics Group Inc's market cap, and Sirius XM Holdings Inc pays a 4.1% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sirius XM Holdings Inc for 102 Days and TransMedics Group Inc for 24 Days on average.

SIRITMDX
Market Cap
$8.87B$2.74B
Volume
4,324,672949,331
Sector
MediaHealth
52-Week High
$32.59$150.42
52-Week Low
$19.92$61.99
Typical Hold Time
102 Days24 Days
Enterprise Value
$18.16B$3.13B
Dividend Yield
4.1%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sirius XM Holdings Inc

Sirius XM (SIRI) trades at $26.51, up 2.16% with mixed technical signals showing neutral momentum. The company demonstrates solid fundamentals with a P/E of 10.57 and P/B of 0.75, though recent earnings show volatility with two misses and one beat in the last four quarters. Strong cash flow generation and a new YouTube partnership provide growth catalysts, while high debt levels and competitive pressures remain concerns.

The stock presents a compelling value opportunity with analyst consensus pointing to 30% upside to the $34.43 price target. However, execution risks in advertising expansion and subscription growth, coupled with $10.31 billion in long-term debt, require careful monitoring. Recent institutional buying and positive management commentary suggest confidence in the company's strategic direction.

TransMedics Group Inc

TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.

The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

SIRI
100% Buy0% Sell
Avg holding period · 102 Days
TMDX
95% Buy5% Sell
Avg holding period · 24 Days

Top news

Latest headlines on both assets

About Sirius XM Holdings Inc

SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.

Read more on SIRI →

About TransMedics Group Inc

TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.

Read more on TMDX →